Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Feasibility study of paclitaxel plus carboplatin in patients with endometrial cancer: a Japan Kanto Tumor Board study (JKTB trial).

Yamada K, Tanabe H, Imai M, Jobo T, Kudo K, Fujiwara H, Nagata C, Furuya K, Suzuki M, Ochiai K, Tanaka T, Yasuda M.

J Obstet Gynaecol Res. 2013 Jan;39(1):311-6. doi: 10.1111/j.1447-0756.2012.01890.x. Epub 2012 May 28.

PMID:
22639962
2.

Intravenous/intraperitoneal paclitaxel and intraperitoneal carboplatin in patients with epithelial ovarian, fallopian tube, or peritoneal carcinoma: a feasibility study.

Nagao S, Iwasa N, Kurosaki A, Nishikawa T, Ohishi R, Hasegawa K, Goto T, Fujiwara K.

Int J Gynecol Cancer. 2012 Jan;22(1):70-5. doi: 10.1097/IGC.0b013e318234f927.

PMID:
22146766
3.

A pilot trial of TAC (paclitaxel, doxorubicin, and carboplatin) chemotherapy with filgastrim (r-metHuG-CSF) support followed by radiotherapy in patients with "high-risk" endometrial cancer.

Duska LR, Berkowitz R, Matulonis U, Muto M, Goodman A, McIntyre JF, Klein A, Atkinson T, Seiden MV, Campos S.

Gynecol Oncol. 2005 Jan;96(1):198-203.

PMID:
15589601
4.

A pilot study of combination chemotherapy with paclitaxel, pirarubicin, and carboplatin (TPC) for endometrial carcinoma.

Hongo A, Kusumoto T, Nakamura K, Seki N, Kodama J, Hiramatsu Y.

Int J Clin Oncol. 2010 Oct;15(5):476-83. doi: 10.1007/s10147-010-0099-9. Epub 2010 Jun 8.

PMID:
20526888
5.
6.

[Phase II clinical trial of neoadjuvant therapy with carboplatin plus paclitaxel for locally advanced triple-negative breast cancer].

Ma WY, Zhang P, Zhang BL, Wang X, Xu XZ, Zheng S, Wang JY, Cai RG, Yuan P, Ma F, Fan Y, Xu BH.

Zhonghua Zhong Liu Za Zhi. 2012 Oct;34(10):770-4. doi: 10.3760/cma.j.issn.0253-3766.2012.10.011. Chinese.

PMID:
23291072
7.

[Evaluation of paclitaxel and carboplatin in patients with endometrial cancer].

Nakamura T, Onishi Y, Yamamoto F, Kouno S, Maeda Y, Hatae M.

Gan To Kagaku Ryoho. 2000 Feb;27(2):257-62. Japanese.

PMID:
10700897
8.

Paclitaxel and carboplatin with amifostine in advanced, recurrent, or refractory endometrial adenocarcinoma: a phase II study of the Southwest Oncology Group.

Scudder SA, Liu PY, Wilczynski SP, Smith HO, Jiang C, Hallum AV 3rd, Smith GB, Hannigan EV, Markman M, Alberts DS; Southwest Oncology Group.

Gynecol Oncol. 2005 Mar;96(3):610-5.

PMID:
15721401
9.

Adjuvant paclitaxel and carboplatin chemotherapy with involved field radiation in advanced endometrial cancer: a sequential approach.

Lupe K, Kwon J, D'Souza D, Gawlik C, Stitt L, Whiston F, Nascu P, Wong E, Carey MS.

Int J Radiat Oncol Biol Phys. 2007 Jan 1;67(1):110-6. Epub 2006 Nov 2.

PMID:
17084542
10.

Comparison of the efficacy between paclitaxel/carboplatin and doxorubicin/cisplatin for concurrent chemoradiation in intermediate- or high-risk endometrioid endometrial cancer: a single institution experience.

Kim HS, Kim JW, Wu HG, Chung HH, Park NH, Song YS, Kang SB, Lee HP.

J Obstet Gynaecol Res. 2010 Jun;36(3):598-604. doi: 10.1111/j.1447-0756.2010.01223.x.

PMID:
20598043
11.

[A feasibility study of doxorubicin/cisplatin (AP) for postoperative chemotherapy in patients with advanced endometrial cancer].

Nishio S, Katsumata N, Tanabe H, Matsumoto K, Yonemori K, Kouno T, Shimizu C, Ando M, Fujiwara Y.

Gan To Kagaku Ryoho. 2006 Nov;33(11):1589-93. Japanese.

PMID:
17108724
12.

A feasibility study of sequential doublet chemotherapy comprising carboplatin-doxorubicin and carboplatin-paclitaxel for advanced endometrial adenocarcinoma and carcinosarcoma.

Ang JE, Shah RN, Everard M, Keyzor C, Coombes I, Jenkins A, Thomas K, A'Hern R, Jones RL, Blake P, Gabra H, Hall G, Gore ME, Kaye SB.

Ann Oncol. 2009 Nov;20(11):1787-93. doi: 10.1093/annonc/mdp193. Epub 2009 Jun 19.

PMID:
19542250
13.
14.

A phase II study of modified dose-dense paclitaxel and every 4-week carboplatin for the treatment of advanced-stage primary epithelial ovarian, fallopian tube, or peritoneal carcinoma.

Abaid LN, Micha JP, Rettenmaier MA, Brown JV, Mendivil AA, Lopez KL, Goldstein BH.

Cancer Chemother Pharmacol. 2013 Jul;72(1):101-7. doi: 10.1007/s00280-013-2173-2. Epub 2013 May 10.

PMID:
23660691
15.

A feasibility study of paclitaxel 225 mg/m(2) and carboplatin AUC = 6 in untreated advanced non-small cell lung cancer patients in Japan.

Ogawara M, Kawahara M, Hosoe S, Atagi S, Kawaguchi T, Okishio K, Naka N, Sunami T, Mitsuoka S, Inoue K, Haryu H, Yoneda T, Origasa H.

Jpn J Clin Oncol. 2002 Feb;32(2):48-53.

PMID:
11948228
16.

Paclitaxel by 24- or 1-hour infusion n combination with carboplatin in advanced non-small cell lung cancer: the Fox Chase Cancer Center experience.

Langer CJ, Leighton JC, Comis RL, O'Dwyer PJ, McAleer CA, Bonjo CA, Engstrom PF, Litwin S, Johnson S, Ozols RF.

Semin Oncol. 1995 Aug;22(4 Suppl 9):18-29.

PMID:
7544025
17.

Phase II prospective study of paclitaxel and carboplatin in older patients with newly diagnosed Müllerian tumors.

Matulonis UA, Krag KJ, Krasner CN, Atkinson T, Horowitz NS, Lee H, Penson RT.

Gynecol Oncol. 2009 Feb;112(2):394-9. doi: 10.1016/j.ygyno.2008.10.015. Epub 2008 Dec 5.

PMID:
19058838
18.

Experience with single-agent paclitaxel consolidation following primary chemotherapy with carboplatin, paclitaxel, and gemcitabine in advanced ovarian cancer.

Micha JP, Goldstein BH, Mattison JA, Bader K, Graham C, Rettenmaier MA, Brown JV, Markman M.

Gynecol Oncol. 2005 Jan;96(1):132-5.

PMID:
15589591
19.

Leuven dose-dense paclitaxel/carboplatin regimen in patients with primary advanced or recurrent endometrial carcinoma.

Vandenput I, Vergote I, Leunen K, Berteloot P, Neven P, Amant F.

Int J Gynecol Cancer. 2009 Aug;19(6):1147-51. doi: 10.1111/IGC.0b013e3181ad3dcb.

PMID:
19820384
20.

Carboplatin and paclitaxel for the treatment of advanced or recurrent endometrial cancer.

Akram T, Maseelall P, Fanning J.

Am J Obstet Gynecol. 2005 May;192(5):1365-7.

PMID:
15902110

Supplemental Content

Support Center